Abstract:e16513 Background: Anti-PD-1 based therapies have been standard-of-care options in both the front-line and treatment refractory settings in RCC, but only 20%~60% of patients respond to ICBs. Current biomarkers often fail to predict benefit of ICBs, so new reliable biomarkers are urgently warranted. Methods: Genomic and transcriptomic data were collected from 3 different ICB-treated RCC cohorts, including Miao et al. (n=53, WES), CheckMate (CM, n=261, WES; n=181, RNA-Seq) and JAVELIN (n=354, RNA-Seq) cohorts. Hallmark pathways downloaded from MSigDB database were used to screened for defective pathways that correlated with PFS using WES data of Miao et al. and CM cohorts. A defective pathway was defined as detecting at least one variant. Enrichment scores were calculated using RNA-seq data of CM cohort based on 28 immune cells gene sets provided by Charoentong et al. Immune cell signatures (ICSs) related to PFS were screened out using cox regression analysis. The selected pathways and ICSs were combined to develop a logistic regression model (10-fold cross-validation) to predict prognosis. Gene expression profiles of CM cohort were randomly split into two groups: 70% as the training set, and the remaining 30% as the test set. The predictive performance was validated in JAVELIN cohort independently. Gene sets expression levels were estimated using ssGSEA and NES methods. ROC curves were used to evaluate the predictive accuracy for 6-month PFS. Survival plots were created using the Kaplan-Meier estimator, and data were analyzed by log-rank test. Results: 7 signatures were selected as input features including 4 pathways (DNA_repair, IFN_alpha, EMT and angiogenesis) identified in Miao et al. and CM cohorts, together with 3 ICSs (Activated.CD4.T.cell, Activated.CD8.T.cell, and Immature.dendritic.cell) identified in CM cohort. Our model showed promising results for predicting 6-month PFS in CM dataset with AUC of 0.984 in the training set and 0.893 in the test set. The prediction of our model outperformed that based on TMB (AUC 0.655 vs. 0.587), GEP (AUC 0.746 vs. 0.823) and PD-L1 (AUC 0.823 vs. 0.768) both in the training and test sets, while combining our model with biomarkers above improved the prediction drastically with AUC of 0.996 in the training set and 0.935 in the test set. Meanwhile, our model maintained preferable performance for differentiating longer PFS from shorter PFS with p vale of 0.021 in JAVELIN cohort. Conclusions: We proposed a risk model to predict prognosis, in which feature selection based on hallmark pathways and immune cell subtypes. Our model showed excellent performance in predicting PFS in RCC patients undergoing immunotherapy, outperforming other ICB-related biomarkers. While combining our model with TMB, GEP, and PD-L1 was correlated more strongly with survival.

Multi-omics Indicators of Long-Term Survival Benefits after Immune Checkpoint Inhibitor Therapy

Delta Radiomics Model for the Prediction of Progression-Free Survival Time in Advanced Non-Small-cell Lung Cancer Patients after Immunotherapy.

Blood Tumor Mutation Burden Can Predict the Clinical Response to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients

Associations Between Interaction Effects of Mutational Events and Efficient Immunotherapy in Squamous NSCLC: Results from 373 Patients.

Predicting Durable Responses to Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Using a Multi-Feature Model

A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy

Clinical multi-dimensional prognostic nomogram for predicting the efficacy of immunotherapy in NSCLC

Association of a deep learning system with progression-free survival (PFS) in patients with renal cell carcinoma (RCC) treated with immune checkpoint blockades (ICBs).

Identification of predictive biomarker for immunotherapy by associating with CD8+T cell Infiltration in lung adenocarcinoma.

Machine learning models for identifying predictors of clinical outcomes with first-line immune checkpoint inhibitor therapy in advanced non-small cell lung cancer

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

Pathological Evaluation of Tumor Immune Microenvironment Before First-Line Anti-Pd1 Plus Anti-Angiogenic Therapy in Patients with Unresectable Hepatocellular Carcinoma (HCC): Towards a Prediction for Treatment Efficacy.

Predictive Model to Identify the Long Time Survivor in Patients with Glioblastoma: A Cohort Study Integrating Machine Learning Algorithms

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma

Incorporating long non-coding RNA (lncRNA) into genome-wide biomarker screening for prognostic gene signatures of immunotherapy outcomes.

A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

A Mutation-Based Gene Set Predicts Survival Benefit after Immunotherapy Across Multiple Cancers and Reveals the Immune Response Landscape

Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients

A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients

Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy

The Potential of Five Immune-Related Prognostic Genes to Predict Survival and Response to Immune Checkpoint Inhibitors for Soft Tissue Sarcomas Based on Multi-Omic Study